FOLH1 and pachyonychia congenita: Among these is the prostate-specific membrane antigen (PSMA) positron emission imaging and computerized tomography (PET/CT), which was approved by the Food and Drug Administration (FDA) in December 2020 and May 2021 for use with 68-Gallium (68-Ga) and piflufolastat (F18) in PC patients, respectively [4].